Chronic hepatitis C infection affects millions of people worldwide and confers significant
morbidity and mortality. Effective treatment is needed to prevent disease progression and …

Abstract The World Health Organization estimates that 71 million people worldwide have
chronic hepatitis C viral infection. A major challenge is overall lack of public awareness of …

Hepatitis C virus (HCV) infection remains a major public health issue with high prevalence in
Taiwan. Recently, the advent of direct-acting antiviral (DAA) agents, with higher efficacy …

Highlights•DAAs for HCV treatment include protease (NS3/4A) inhibitors, RNA-dependent
polymerase (NS5B) inhibitors and NS5A inhibitors.•The combination of DAA owning to …

Summary Background In Egypt, chronic hepatitis C virus (HCV) infection occurs in around
10% of the population (about 8 million individuals), and is a leading cause of liver cirrhosis …

Chronic infection with the hepatitis C virus (HCV) remains a major health problem affecting
approximately 58 million people worldwide. In the era of interferon (IFN)-based regimens …

Chronic hepatitis C virus (HCV) infection is an infection that affects over 71 million people
worldwide that primarily leads to significant morbidity and mortality through its predisposition …

The direct‐acting antiviral regimen of ombitasvir (OBV)/paritaprevir (PTV)/ritonavir
(r)±dasabuvir (DSV)±ribavirin (RBV) demonstrated high rates of sustained viral response at …

Objective We evaluated the efficacy and safety of ledipasvir/sofosbuvir alone and with
ribavirin for 8 and 12 weeks in Egyptian patients with and without cirrhosis, who were …

BACKGROUND Nearly 290000 patients with chronic hepatitis C die annually from the most
severe complications of the disease. One of them is liver cirrhosis, which occurs in about …